A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.

Trial Profile

A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MYCYC
  • Sponsors Aspreva Pharmaceuticals Corporation
  • Most Recent Events

    • 30 Jan 2014 UK clinical research network Database report states accruel to date as 100%
    • 16 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top